

# Pfizer's Commitment to Transparency Reporting

Throughout the life cycle of a vaccine or medicine, pharma companies work with scientists and healthcare professionals on a number of activities to address patient needs. These collaborations include research and development, sharing best clinical practice and exchanging information on how new medicines fit into established clinical treatment pathways.

Innovative Medicines Canada (IMC) and its member companies have adopted disclosure guidelines to ensure that the interactions of their member companies with healthcare professionals and organizations meet the highest standards of integrity and transparency. Building greater transparency into the relationships between pharmaceutical companies and these stakeholders aim to build understanding of the collaboration and recognition of its value to patient care.

In June 2024, Pfizer began publishing aggregated sums of fees to Canadian Healthcare Professionals (HCPs) for services as well as funding to Healthcare Organizations (HCOs) per the IMC Code. The Voluntary Framework on Disclosure of Payments was developed by IMC and includes:

1.

One sum total of the company's fees to HCPs for services such as speaking, advising, and/or consulting.

2.

One sum total of the company's funding to HCOs, which supports efforts such as philanthropic (charitable), educational and/or scientific activities.

3.

One sum total of the company's funds provided to HCPs to support their travel and expenses to attend international meetings.

Patient Advocacy Groups (PAG) and Charitable Organizations aim to support and advocate for people living with a particular disease or medical condition. Working with PAGs allows Pfizer to support their activities, where appropriate, and to better understand patients' unmet needs and how those needs can best be met. By obtaining patient insights, we gain a better knowledge of the burden of disease, which informs our efforts to develop medicines and support programs for the patient community.

Pfizer is committed to financial transparency across the healthcare sector, and therefore goes beyond the IMC Code to publish an aggregated sum of our contributions to PAGs and to Charitable Organizations.

4.

One sum total of Pfizer's contributions to Patient Advocacy Groups and Charitable Organizations.

Innovative medicines and vaccines enable us to help people living with all types of diseases. Clinical trials help progress the development of treatments by testing the safety and efficacy of potential new medicines or vaccines. Pfizer proudly partners with Canadian healthcare organizations to conduct clinical trials, and it's these clinical trials that help lead to new medicines and vaccines. Transparency in clinical trial funding is essential to portray a complete picture of Pfizer's financial and scientific investments in Canada. IMC does not require clinical trial funding to be publicly disclosed, yet to show its commitments to financial transparency, Pfizer reports our investments to HCOs to conduct independent research, as well as to conduct Pfizer sponsored clinical trials.

5.

One sum total of Pfizer's financial investment for HCOs to conduct independent research grants such as Investigator Sponsored Research and Clinical Research Collaborations.

6.

One sum total of Pfizer's funding to HCOs to conduct clinical trials for Pfizer investigational products.

This reflects our commitment to increasing transparency around the support Pfizer provides to organizations that work to advance science and patient care. This support is one way we contribute to the advancement of scientific research, in conjunction with our core business of developing innovative medicines.

We believe that transparency is essential to building and maintaining trust in us and in our medicines and we support the work being done by Innovative Medicines Canada to improve transparency across the pharmaceutical industry.

Category of Funding	2023 Reporting
IMC- Fee for HCP Services	\$5,924,129.11
IMC- HCO Funding	\$10,451,390.29
IMC- HCP Sponsorships	\$569,261.21
PAG & Charitable Organizations Contributions	\$12,489,504.55
Research Grants to HCOs	\$10,033,705.69
Clinical Trial Funding to HCOs	\$32,337,798.05

**Note**

While Pfizer makes every effort to present reliable and accurate information and data, Pfizer makes no warranty nor assumes legal responsibility or liability for the accuracy or completeness of the information contained above. Pfizer shall not be held liable for damages resulting from the use or misuse of the information or data contained on this website. Certain links may lead to resources located on servers that are not maintained by Pfizer or under its control, and such hypertext links are provided as a convenience only. The inclusion of a link does not imply endorsement by or of the referenced site and Pfizer is not responsible for the contents of or the availability of access to such websites.